Direct-to-consumer genetic testing: Reliable or risky?

Clinical Chemistry

Volumn 57, Issue 12, 2011, Pages 1641-1644

  Spencer, David H ^a   Lockwood, Christina ^a   Topol, Eric ^b   Evans, James P ^c   Green, Robert C ^d   Mansfield, Elizabeth ^e   Tezak, Zivana ^e  

^a BARNES JEWISH HOSPITAL   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOPIDOGREL;

CERTIFICATION; CONSUMER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIRECT TO CONSUMER GENETIC TESTING; GENE SEQUENCE; GENETIC COUNSELING; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GOVERNMENT REGULATION; HEALTH CARE COST; HUMAN; MEDICAL INFORMATION; NOTE; PHARMACOGENOMICS; PHYSICIAN; SAFETY; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM;

CONSUMER PARTICIPATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; HUMANS; PHARMACOGENETICS; PRIVATE SECTOR; PROBABILITY; RISK FACTORS;

EID: 82755190462     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.167197     Document Type: Note

References (0)